Tiotropium and the risk of death in COPD

New England Journal of Medicine

Volumn 370, Issue 5, 2014, Pages 480-483

  Loke, Yoon K ^a   Singh, Sonal ^b   Furberg, Curt D ^c  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TIOTROPIUM BROMIDE; BRONCHODILATING AGENT; SCOPOLAMINE DERIVATIVE;

CAUSE OF DEATH; CHRONIC OBSTRUCTIVE LUNG DISEASE; DEATH; DISEASE ASSOCIATION; DRUG DOSE COMPARISON; DRUG FATALITY; DRUG SAFETY; HEART INFARCTION; HUMAN; INHALER; LETTER; MORTALITY; PRIORITY JOURNAL; RISK ASSESSMENT; FEMALE; MALE; NOTE; CARDIOVASCULAR DISEASE; META ANALYSIS (TOPIC);

BRONCHODILATOR AGENTS; FEMALE; HUMANS; MALE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SCOPOLAMINE DERIVATIVES;

EID: 84893090796     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1314411     Document Type: Letter

References (3)

1. Wise RA, Anzueto A, Cotton D, et al. Tiotropium Respimat inhaler and the risk of death in COPD. N Engl J Med 2013;369:1491-501.
2. Verhamme KM, Afonso A, Romio S, Stricker BC, Brusselle GG, Sturkenboom MC. Use of tiotropium Respimat Soft Mist Inhaler versus HandiHaler and mortality in patients with COPD. Eur Respir J 2013;42:606-15.
3. Jenkins CR. More than just reassurance on tiotropium safety. N Engl J Med 2013;369:1555-6.